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ABSTRACT
Background A core feature of chronic obstructive
pulmonary disease (COPD) is the accelerated decline in
forced expiratory volume in one second (FEV1). The
recent Groningen and Leiden Universities study of
Corticosteroids in Obstructive Lung Disease (GLUCOLD)
study suggested that particular phenotypes of COPD
beneﬁt from ﬂuticasone±salmeterol by reducing the rate
of FEV1 decline, yet the underlying mechanisms are
unknown.
Methods Whole-genome gene expression proﬁling
using the Affymetrix Gene ST array (V.1.0) was
performed on 221 bronchial biopsies available from
89 COPD patients at baseline and after 6 and
30 months of ﬂuticasone±salmeterol and placebo
treatment in GLUCOLD.
Results Linear mixed effects modelling revealed that
the expression of 138 genes decreased, whereas the
expression of 140 genes signiﬁcantly upregulated after
both 6 and 30 months of treatment with ﬂuticasone
±salmeterol versus placebo. A more pronounced
treatment-induced change in the expression of 50 and
55 of these 278 genes was associated with a lower rate
of decline in FEV1 and Saint George Respiratory
Questionnaire, respectively. Genes decreasing with
treatment were involved in pathways related to cell cycle,
oxidative phosphorylation, epithelial cell signalling,
p53 signalling and T cell signalling. Genes increasing
with treatment were involved in pathways related to
focal adhesion, gap junction and extracellular matrix
deposition. Finally, the ﬂuticasone-induced gene
expression changes were enriched among genes that
change in the airway epithelium in smokers with versus
without COPD in an independent data set.
Conclusions The present study suggests that gene
expression in biological pathways of COPD is dynamic
with treatment and reﬂects disease activity. This study
opens the gate to targeted and molecular phenotype-
driven therapy of COPD.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is
one of the most common chronic diseases in adults
with a worldwide prevalence that increases to more
than 10% of adults older than 65 years.1 It is char-
acterised by chronic progressive lung function
decline in association with an inﬂammatory
response of the airways to noxious particles or
gases. Thus far, distressingly little is known about
the underlying pathophysiology responsible for this
chronic inﬂammation and relentless disease pro-
gression, processes that persist for years even after
individuals quit smoking. There is neither a curative
therapy nor a pharmacological intervention that is
generally accepted to be disease modifying.2
Together with the high prevalence of COPD, this
indicates a high medical need and an urgent scien-
tiﬁc challenge.
The long-term effects of inhaled corticosteroids
(ICS) in COPD have been reported in several
studies, but with conﬂicting results and their role in
COPD management continues to be subject to
much debate.3–5 Recently, the Groningen and
Leiden Universities study of Corticosteroids in
Obstructive Lung Disease (GLUCOLD) yielded
more positive effects than most studies so far.6 In
this randomised placebo-controlled study, the long-
term effects of ﬂuticasone or ﬂuticasone/salmeterol
were investigated in patients with COPD.6 As could
be expected, patients treated with placebo experi-
enced a considerable decline in forced expiratory
volume in one second (FEV1) of −79 (95% CI
−112 to −46) mL/year between 6 and 30 months
of follow-up. Remarkably, treatment with ﬂutica-
sone or ﬂuticasone/salmeterol signiﬁcantly dimin-
ished the rate of FEV1 decline, being close to zero
for ﬂuticasone and only −16 (95% CI −46 to 15)
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Key messages
What is the key question?
▸ What are the underlying mechanisms of the
long-term beneﬁcial effects of corticosteroids
on FEV1 decline in COPD?
What is the bottom line?
▸ Airway gene expression in COPD is dynamic
with treatment and associates with clinical
response.
Why read on?
▸ Our ﬁndings provide much needed insight into
the biological pathways that reﬂect and
potentially mediate treatment-induced clinical
improvement in COPD.
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mL/year for ﬂuticasone/salmeterol.6 The larger beneﬁts by ICS
observed in this study as compared with previous ones raise the
concept that phenotypic characteristics are determining treat-
ment effects in COPD.
The aim of the present study was to investigate the under-
lying mechanisms of the long-term beneﬁcial effects of corti-
costeroids on FEV1 decline in COPD. To this end,
genome-wide gene expression proﬁling was performed in
bronchial biopsies from COPD patients who participated in
the GLUCOLD study before and during treatment with
inhaled ﬂuticasone±salmeterol or placebo.6 Findings were
validated using a different group of COPD patients rando-
mised to 6 months ﬂuticasone followed by 24-month placebo,
allowing the validation of gene expression changes associated
with treatment and their reversion to baseline levels following
treatment cessation.
METHODS
Patients and study design
All COPD patients participating in the GLUCOLD study were
included. The inclusion and exclusion criteria have been previ-
ously described.6 In the GLUCOLD study, patients were ran-
domly assigned to receive one of four treatments in a blinded
way for patients, clinicians and researchers: (1) ﬂuticasone
500 μg twice daily for 30 months; (2) ﬂuticasone/salmeterol
500/50 μg twice daily for 30 months, (3) placebo twice daily for
30 months or (4) ﬂuticasone 500 μg twice daily for the ﬁrst
6 months followed by placebo twice daily for 24 months.
During follow-up, spirometry was performed every 3 months.
In addition, a bronchoscopy with biopsies of the central airways
was performed before and 6 and 30 months after treatment.
The study was approved by the local medical ethics committees
and all patients gave their written informed consent. A consort
diagram showing the number of bronchial biopsies available for
microarray analysis at each time point (baseline and after 6 and
30 months of treatment) is presented in ﬁgure 1. The methods
for RNA isolation and size fractionation, Affymetrix Human
Gene ST V.1.0 microarray hybridisation, data normalisation,
quality control as well as PCR validation are described in the
online supplementary material.
Statistical analyses
All statistical analyses were performed with the R statistical soft-
ware V.2.12.0.
Identiﬁcation of genes that change after treatment with
ﬂuticasone±salmeterol in the ﬁrst three treatment arms
To investigate which genes changed after treatment, we analysed
gene expression levels in bronchial biopsies of COPD patients
who were treated for 30 months with ﬂuticasone±salmeterol or
placebo. Since the clinical and anti-inﬂammatory effects of long-
term treatment with ﬂuticasone and ﬂuticasone/salmeterol were
comparable, these treatment arms were analysed together as this
increases the power of our study. Thus, treatment was deﬁned as
a factor with two levels: placebo versus treatment (ﬂuticasone
with or without added salmeterol). Time was deﬁned as a cat-
egorical factor with three levels: 0, 6 and 30 months. Smoking
status and RNA integrity number (RIN) scores for each subject
and at each time point were included as covariates and patient
as a random effect variable. Next, we performed an analysis of
variance (ANOVA) to compare linear mixed effect model 1 with
linear mixed effect model 2 for each gene as described below,
where Geij represents the log2 gene expression value for a gene
in sample i from patient j, ɛij represents the error that is
Figure 1 Consort diagram of the Groningen and Leiden Universities study of Corticosteroids in Obstructive Lung Disease (GLUCOLD) study showing
the total number of biopsies available at each time point. In the GLUCOLD study, patients were withdrawn from further analysis if their adherence to
treatment was below 70%.
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assumed to be normally distributed and αj represents the patient
random effect:
Geij ¼ b0 þ b1XRINi þ b2XSmoking Statusi þ b3XTreatmenti
þ b4XTimei þ b5XTreatmenti:Timei þ 1ij þ aj: ð1Þ
Geij ¼ b0 þ b1XRINi þ b2XSmoking Statusi þ b3XTreatmenti
þ b4XTimei þ 1ij þ aj: ð2Þ
To control for multiple testing, a false discovery rate (FDR)
below 0.25 was maintained.7 Next, the coefﬁcients from the
interaction term β5iXTreatment:Time from linear mixed effect
model 1 were used to select those genes that changed signiﬁ-
cantly (at a nominal p value <0.05) and in the same direction
after both 6 and 30 months of treatment with ﬂuticasone±sal-
meterol versus placebo. A summary of methods and key results
is presented in ﬁgure 2.
Additional information on the statistical approach to investi-
gate association between treatment-induced change in gene
expression and change in FEV1 is provided in online supple-
mentary material.
Validation in a separate treatment arm of GLUCOLD
To validate our ﬁndings, we used the fourth GLUCOLD study
arm as validation set consisting of 6-month treatment with ﬂuti-
casone followed by 24-month treatment with placebo. We
assessed whether (1) genes identiﬁed as being affected by treat-
ment with ﬂuticasone±salmeterol would change similarly after
6-month treatment with ﬂuticasone in the fourth study arm and
(2) these genes would revert towards baseline in the 24-month
interval after treatment was discontinued and patients switched
to placebo. For these analyses, we used the same linear model 1
as described above and considered a difference with a nominal
p value <0.05 to be statistically signiﬁcant.
Functional enrichment analysis
Functional enrichment analysis was performed using Gene Set
Enrichment Analysis (GSEA) V.2.07.8 A more detailed descrip-
tion is provided in the online supplementary material. GSEA
was also used to examine the relationships between gene expres-
sion differences associated with treatment and those associated
with COPD using an independent gene expression data set of
bronchial brushes from patients with and without COPD.9 To
this end, genes were ranked according to the strength of their
t-statistic reﬂecting their association with the presence of COPD
and GSEA was applied to investigate if genes that change with
treatment are upregulated or downregulated in COPD.9
RESULTS
Patient population
A total of 89 out of 114 randomised COPD patients in
GLUCOLD had two or more frozen biopsies available with
RNA and microarray data of sufﬁcient quality for analysis and
were included in the study (ﬁgure 1 shows the consort
diagram). Their clinical characteristics are summarised in
table 1.
Changes in airway gene expression after both 6 and
30 months of treatment
An outline of the analytical approach and the main study results
is presented in ﬁgure 2. Using ANOVA, we identiﬁed a total of
1650 genes changing with ﬂuticasone±salmeterol versus
placebo after either 6 or 30 months of treatment (FDR<0.25).
Next, we explored the change in the expression of these 1650
genes at two different time points, that is, 0–6 and
0–30 months. The expression of 138 out of these 1650 genes
were signiﬁcantly downregulated (List D), whereas the expres-
sion of 140 genes were signiﬁcantly upregulated (List U) after
both 6 and 30 months with a nominal p value <0.05. Thus, we
identiﬁed a total of 278 genes (List D+List U) that were
Figure 2 Summary of the methods and key results.
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Table 1 Patient characteristics
Fluticasone±salmeterol for 30 months Placebo for 30 months
Fluticasone for 6 months followed by placebo
between 6 and 30 months
Baseline 6 months 30 months Baseline 6 months 30 months Baseline 6 months 30 months
Number of included patients 45 23 21
Number of biopsies available at each time point 37 39 31 21 17 17 21 21 17
Male/female, n 41/4 19/4 19/3
Age, years 62.4±7.2 60.2±7.8 63.1±7.4
BMI 25.5±3.7 24.2±3.9 25.4±3.6
Current smokers, n (%) 22 (59) 20 (51) 14 (45) 14 (67) 10 (59) 8 (47) 10 (48) 9 (43) 8 (47)
RIN score 3.3±1.5 3.5±1.3 4.8±1.5** 3.5±1.3 3.9±1.6 5.2±1.8** 3.3±1.7 3.7±1.7 3.7±1.5
FEV1, % predicted 62.6±9.0 63.6±10.7 64.2±12.3 61.3±8.80 62.3±9.20 57.0±8.3 64.7±8.62 64.9±9.0 64.2±12.5
Reversibility, % predicted FEV1 6.9±5.3 7.1±4.8 7.3±5.4
PC20 methacholine, (mg/mL)‡ 0.43 (0.01–14.45) 0.95 (0.04–8.53) 0.45 (0.04–76.80)
RV, % predicted 147.1±37.3 140.5±29.3 135.1±34.5 146.0±25.9 144.9±31.0 139.3±20.9 145.2±36.4 137.0±34.5 134.2±34.6
RV/TLC, % predicted 123.2±19.0 119.9±18.6 116.3±25.0 125.2±16.9 123.6±16.8 120.4±14.0 124.7±19.1 120.6±19.5 118.6±21.1
TLCO, % predicted 65.9±20.0 68.7±19.9 63.5±19.8 58.6±18.0 59.8±16.0 59.4±14.0 68.9±24.5 69.2±25.3 71.0±25.3
SGRQ 29.4±12.4 28.7±15.5 26.8±14.6 30.6±18.6 32.8±21.0 33.4±20.1 27.6±15.6 26.8±15.0 22.12±15.2
Bronchial biopsies, n/0.1 mm2
Macrophages† 1.08±0.32 0.70±0.34** 0.73±0.58** 0.98±0.40 0.76±0.36 0.87±0.42 0.96±0.22 0.74±0.35* 0.86±0.52
Neutrophils† 0.75±0.32 0.93±0.37* 1.1±0.46** 0.76±0.37 0.77±0.39 0.89±0.42 0.77±0.33 0.80±0.35 1.13±0.52*
Eosinophils† 0.49±0.43 0.26±0.35* 0.64±0.60 0.53±0.53 0.33±0.42 0.47±0.48 0.68±0.53 0.22±0.36** 0.86±0.72
CD4 cells† 1.82±0.30 1.08±0.32** 1.30±0.39** 1.65±0.39 1.52±0.35 1.40±0.40 1.60±0.27 1.22±0.46** 1.47±0.42
CD8 cells† 1.44±0.39 0.87±0.32** 0.90±0.39** 1.31±0.38 1.14±0.26 1.28±0.29 1.10±0.42 0.88±0.37 1.03±0.51
Mast cells† 1.42±0.23 0.77±0.33** 0.61±0.41** 1.41±0.17 1.02±0.18** 1.15±0.18** 1.49±0.21 0.79±0.30** 1.03±0.25**
Intact epithelium, %† 1.37±0.34 1.34±0.25 1.27±0.30 1.34±0.39 1.24±0.26 0.89±0.52** 1.34±0.44 1.26±0.29 1.14±0.42
Data are presented as mean± SD unless stated otherwise. Differences in variables before and after treatment were analysed using a two-sided, paired, Student’s t test.
*p<0.05 versus baseline, **p<0.01 versus baseline.
†Log transformed.
‡Geometric mean with range between brackets.
BMI, body mass index; FEV1, forced expiratory volume in one second; PC20, provocative concentration [or dose] causing a 20% fall in FEV1; RIN, RNA integrity number; RV, residual volume; SGRQ, Saint George Respiratory Questionnaire; TLC, total lung
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similarly changed after 6 and 30 months of treatment with ﬂuti-
casone±salmeterol compared with placebo (ﬁgure 3). To assess
whether these treatment-associated changes in gene expression
were due to differences in inﬂammatory and epithelial cell
numbers, we adjusted for changes in the number of neutrophils,
eosinophils, macrophages, lymphocytes, mast cells and epithelial
cells in bronchial biopsies. A total of 87% and 83% of the
278 genes remained signiﬁcantly associated with treatment after
6 and 30 months, respectively. To determine whether the pres-
ence of salmeterol in addition to ﬂuticasone in a subgroup of
our treatment patients inﬂuenced the analysis, we also modelled
airway gene expression in patients treated with ﬂuticasone and
with ﬂuticasone/salmeterol separately and found that more than
97% of treatment-induced gene expression changes were con-
cordant, that is, changed in the same direction after 6 and
30 months of treatment in both treatment groups. Finally, we
found that a higher baseline expression of 11 out of the 138
List D genes was associated with a less severe airﬂow obstruc-
tion, as reﬂected by FEV1% predicted at baseline (nominal p
value <0.05). Vice versa, a higher baseline expression of 18 out
of the 140 List U genes was associated with a more severe
COPD.
Validation of treatment effects in a separate treatment arm
within GLUCOLD
To validate the association of gene expression in patients with
COPD treated with ﬂuticasone, we used microarray data from 21
patients in the fourth treatment arm of GLUCOLD consisting of
treatment with ﬂuticasone for 6 months followed by 24-month
placebo. After 6 months of treatment with ﬂuticasone, a total of
77 of the List D (downregulated genes, 56%) and 78 of the List
U (upregulated genes, 56%) changed both signiﬁcantly (nominal
p value <0.05) and in the same direction as shown in the
primary analysis. A total of 50 of the 278 genes signiﬁcantly
changed both in the same direction after 6-month ﬂuticasone
treatment and in the opposite direction after ﬂuticasone with-
drawal (table 2 and see online supplementary ﬁgure S1).
Association between long-term (between 0 and 30 months)
changes in gene expression and rate of decline in FEV1 and
SGRQ
To further investigate the relationship between the magnitude of
treatment-induced changes in gene expression and the clinical
response to treatment, we investigated whether patients with
more pronounced gene expression changes had a better improve-
ment in FEV1 and health status, as reﬂected by the total Saint
George Respiratory Questionnaire (SGRQ) score, than those
with more modest treatment-induced gene expression changes.
We did not ﬁnd any gene for which a higher change in expression
after 6 months was associated with better improvement in FEV1.
In contrast, a more pronounced change in the expression of 42
of the List D (downregulated genes, 30%) and 8 of the List U
(upregulated genes, 6%) was associated with a lower rate of
decline in FEV1 between 0 and 30 months with a nominal p
value <0.05 (see online supplementary table S1). In addition, a
more pronounced change in the expression of 26 of the List D
and 29 of the List U genes was associated with a lower rate of
decline in SGRQ between 0 and 30 months with a nominal p
value <0.05 (see online supplementary table S2). Finally, a more
pronounced change in the expression of 18 of the List D and 3
of the List U genes was associated with both a lower decline in
FEV1 and SGRQ. To further investigate the effects of treatment
on gene expression in association with clinical improvement, we
performed a cluster analysis in patients treated with ﬂuticasone
±salmeterol based on the change in expression of these 18 List D
and 3 List U genes (ﬁgure 4A). Next, we selected ‘treatment
responders’ and ‘treatment non-responders’ as demonstrated in
ﬁgure 4A. Treatment responders had a lower decline in SGRQ
between 0 and 30 months than treatment non-responders
(p=0.003) or patients treated with placebo and tended to have a
lower decline in FEV1 (p=0.06) (ﬁgure 4B and C).
PCR validation of candidate gene expression changes
with treatment that associate with therapeutic response
PCR measurements were performed on the six genes for which
the treatment-induced change in expression between 0 and
30 months was most strongly associated with the change
Figure 3 Heat map showing the changes in expression of the 278 genes (List D, downregulated and List U, upregulated) that are signiﬁcantly
affected after (A) 0–6 and (B) 0–30 months of treatment with ﬂuticasone±salmeterol compared with placebo.
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Table 2 List of 50 genes that changed significantly after both 6 and 30 months of treatment with fluticasone±salmeterol and could be
confirmed in the fourth GLUCOLD treatment arm by both a change in the same direction after 6 months fluticasone treatment and a change in
the opposite direction after fluticasone withdrawal
Gene symbol
Change after 6 and 30 months of treatment with fluticasone
±salmeterol versus placebo
Change after 6 months fluticasone treatment and after









Fold change p Value Fold change p Value Fold change p Value Fold change p Value
TMPRSS11D −1.959 <0.001 −1.842 0.001 −1.746 0.006 1.341 0.030
SERPINB13 −2.126 0.001 −1.686 0.041 −1.919 0.023 1.432 0.035
SPINK5 −2.200 0.001 −1.631 0.032 −1.902 0.013 1.424 0.031
KRT4 −3.592 <0.001 −1.554 0.030 −3.485 0.003 1.711 0.002
TMPRSS11A −3.329 <0.001 −1.552 0.014 −1.125 <0.001 2.092 <0.001
CSTA −2.292 <0.001 −1.485 0.016 −2.259 0.004 1.567 0.008
GABRP −1.624 0.002 −1.440 0.007 −1.660 <0.001 1.260 0.017
TYMS −1.930 <0.001 −1.417 0.023 −1.802 0.002 1.372 0.005
GPR87 −1.723 <0.001 −1.375 0.017 −1.619 0.007 1.230 0.025
TMPRSS4 −1.816 <0.001 −1.358 0.027 −1.655 0.007 1.279 0.009
ATP10B −1.498 0.003 −1.358 0.023 −1.437 0.017 1.299 0.033
CH25H −1.531 0.004 −1.335 0.023 −1.601 0.001 1.476 0.004
SRPX2 −1.723 <0.001 −1.317 0.022 −1.643 0.010 1.341 0.025
IGKC −1.603 0.002 −1.312 0.045 −1.533 0.006 1.792 0.016
BNIPL −1.501 0.002 −1.291 0.012 −1.532 <0.001 1.141 0.033
RAB38 −1.522 0.001 −1.281 0.025 −1.497 0.002 1.167 0.033
CAPNS2 −1.707 <0.001 −1.275 0.040 −1.708 <0.001 1.276 0.023
FANCD2 −1.443 <0.001 −1.261 0.014 −1.323 0.003 1.137 0.044
ABCC1 −1.529 <0.001 −1.241 0.026 −1.418 0.009 1.271 0.005
ODZ2 −1.504 0.001 −1.237 0.029 −1.425 0.023 1.295 0.034
BNC1 −1.495 <0.001 −1.233 0.027 −1.406 0.028 1.178 0.028
KLK10 −1.464 0.008 −1.221 0.037 −1.429 0.013 1.289 0.027
PTAFR −1.366 0.002 −1.218 0.025 −1.284 0.008 1.210 0.006
CRABP2 −1.680 <0.001 −1.213 0.034 −1.582 0.008 1.568 <0.001
ODZ4 −1.281 0.001 −1.169 0.015 −1.311 0.001 1.169 0.016
TRIM16 −1.496 <0.001 −1.167 0.035 −1.594 0.001 1.244 0.033
EYA2 −1.213 0.010 −1.160 0.021 −1.187 0.034 1.121 0.021
GNA15 −1.555 <0.001 −1.154 0.048 −1.474 0.013 1.191 0.028
SMAGP −1.422 <0.001 −1.152 0.019 −1.383 0.002 1.210 0.002
BICD2 −1.309 <0.001 −1.145 0.026 −1.240 0.022 1.170 0.014
EXOSC7 −1.211 0.001 −1.141 0.027 −1.156 0.015 1.103 0.015
SCO1 −1.158 0.013 −1.134 0.037 −1.175 0.020 1.083 0.006
BID −1.171 0.011 −1.132 0.039 −1.168 0.015 1.125 0.046
C12orf32 −1.213 0.001 −1.122 0.025 −1.253 0.005 1.113 0.035
ITPA −1.293 <0.001 −1.108 0.029 −1.212 0.021 1.169 0.005
TSPAN17 −1.259 <0.001 −1.102 0.025 −1.201 0.015 1.208 0.004
FKBP5 1.931 <0.001 2.284 <0.001 1.791 <0.001 −1.389 0.011
PDK4 1.689 0.001 1.719 0.002 1.726 <0.001 −1.486 0.014
RHOBTB3 1.469 <0.001 1.519 0.003 1.511 <0.001 −1.629 0.003
ART3 1.570 0.003 1.411 0.016 1.446 0.015 −1.235 0.019
PPM1K 1.397 <0.001 1.326 0.004 1.285 <0.001 −1.446 0.004
HIF3A 1.342 0.007 1.304 0.005 1.248 0.039 −1.116 0.034
KLF9 1.217 0.020 1.292 <0.001 1.276 0.003 −1.084 0.037
SLC39A8 1.319 0.002 1.238 0.033 1.399 <0.001 −1.265 0.015
PDE4DIP 1.331 0.001 1.236 0.010 1.291 0.003 −1.192 0.021
PHF17 1.325 <0.001 1.233 0.011 1.249 0.001 −1.305 0.001
KLF15 1.340 0.003 1.217 0.019 1.299 0.008 −1.166 0.022
KCNAB1 1.386 0.001 1.216 0.038 1.347 0.009 −1.252 0.002
PRPH 1.201 0.005 1.178 0.010 1.174 0.017 −1.092 0.006
TMX4 1.167 0.003 1.111 0.047 1.176 0.013 −1.270 0.001
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in FEV1: cellular retinoic acid-binding protein 2 (CRABP2),
B-cell lymphoma protein 2/adenovirus E1B 19kD interacting
protein like (BNIPL), adenosine triphosphate (ATP)-binding cas-
sette subfamily A (ABC1), ATP-binding cassette subfamily A
member 12 (ABCA12), dual oxidase maturation factor-1
(DUOXA1), grainyhead-like 3 (GRHL3) and protein phosphat-
ase, Mg2+/Mn2+ dependent, 1 K (PPM1K). Measurements
were performed in both the baseline and 30-month time point
samples from four patients treated with placebo and four
patients treated with ﬂuticasone±salmeterol. PCR of all genes
changed in the same direction, the fold difference between treat-
ment with ﬂuticasone±salmeterol versus placebo ranging from
−9.52 to+10.85 (see online supplementary ﬁgure S2).
Functional analyses of gene expression signatures
In order to explore the biological pathways reﬂected in the gene
expression signatures, GSEA was performed. The GSEA results
for gene sets representing Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways are summarised in online supple-
mentary table S3 and the supplementary ﬁle
‘listofKEGGpathwaygenes.pdf ’. Guided by our ﬁndings of
enrichment for pathways involved in cell–cell and cell–extracel-
lular matrix interactions from this analysis, we performed litera-
ture mining to compose a gene set consisting of genes involved
in epithelial barrier function (see online supplementary table
S4). Signiﬁcant enrichment was observed for epithelial barrier
function genes among those with increased expression following
30-month treatment (ﬁgure 5A).
Treatment-related changes in airway gene expression
associate with COPD disease activity in an independent
cohort
In order to evaluate whether the treatment-related changes in
airway gene expression from GLUCOLD are associated with
disease activity in an independent cohort, GSEA was performed
on a whole-genome gene expression data set derived from bron-
chial brushings of smokers with (n=87) and without (n=151)
COPD.9 Figure 5B shows that genes being downregulated with
treatment (List D) are signiﬁcantly enriched among genes that
are expressed at higher levels in an independent data set of
airway epithelium from patients with COPD relative to
non-COPD controls (GSEA FDR<0.001). Similarly, genes upre-
gulated after treatment with ﬂuticasone±salmeterol (List U) are
signiﬁcantly enriched among genes that are expressed at lower
levels in patients with COPD in this independent data set
(GSEA FDR <0.001, ﬁgure 5B). In addition, we assessed which
of the 278 List D and List U genes were differently expressed in
COPD versus controls. A total of 39 of the 138 List D genes
Figure 4 (A) Hierarchically clustered heat map showing changes in the expression of the 18 List D and 3 List U genes of which a higher
magnitude of change in expression was associated with both a lower decline in forced expiratory volume in one second (FEV1) as well as Saint
George Respiratory Questionnaire (SGRQ) between 0 and 30 months. Only patients treated with ﬂuticasone±salmeterol were included. Treatment
responders and non-responders were selected based on a cluster analysis. (B) Treatment responders had a better long-term SGRQ than treatment
non-responders and chronic obstructive pulmonary disease patients treated with placebo and (C) tended to have a better long-term FEV1 than
treatment non-responders.
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were upregulated in COPD, whereas 21 of the 140 List U genes
were downregulated in COPD (FDR q value <0.05 (see online
supplementary table S5 and ﬁgure S3).
Additional information
All microarray data from samples in this study have been depos-
ited in gene expression omnibus under accession #36221. Of
the 101 COPD patients included in the GLUCOLD study, bron-
chial biopsies were available in only 65 subjects at 30 months. It
could be argued that this may have caused a selection bias in
favour of drug treatment, since clinically worse patients drop
out and adherent subjects do better. For this reason, we analysed
the baseline clinical characteristics of the 65 patients from
whom bronchial biopsies were available versus the remaining 36
patients (see online supplementary table S6). Both groups had a
comparable severity of their COPD, which makes a selection
bias in favour of drug treatment unlikely.
DISCUSSION
Our study has identiﬁed 278 genes that change in expression
after treatment with ﬂuticasone±salmeterol versus placebo in
patients with moderate-to-severe COPD.
We validated these treatment-associated changes in gene
expression in a separate study arm consisting of 21 patients who
received ﬂuticasone for 6 months followed by treatment with-
drawal. We found that a more pronounced treatment-induced
downregulation of gene expression was signiﬁcantly associated
with a lower rate of decline in FEV1 as well as health status
measured with the SGRQ. In addition, gene expression proﬁling
in an independent COPD-control data set showed that the
ﬂuticasone-induced pattern of gene expression was the converse
of the one associated with the presence of COPD. Thus,
ﬂuticasone-induced gene expression mirrored that of
non-COPD patients. Together our ﬁndings suggest that inhaled
ﬂuticasone alters the expression of genes related to COPD
disease activity.9 These observations are consistent with the clin-
ical beneﬁts of ﬂuticasone observed in the GLUCOLD trial.6
Many of the treatment-induced gene expression differences
associated with clinical improvement occur in genes involved in
functions relevant to COPD. For example, DUOXA1 induces
oxidative stress by generation of hydrogen peroxide via regula-
tion of dual oxidase-1 (DUOX1).10 Oxidative stress, in turn, acti-
vates the inﬂammatory response by activation and subsequent
nuclear localisation of nuclear factor kappa-light-chain-enhancer
Figure 5 Gene set enrichment analysis (GSEA). (A) Enrichment of genes involved in epithelial barrier function among upregulated genes after
treatment with ﬂuticasone±salmeterol. The colour bar indicates the genes ranked according to their change in expression after 30-month treatment
with ﬂuticasone±salmeterol (blue representing a treatment-induced decrease and red an increase in gene expression). The vertical bars indicate the
epithelial barrier function genes with the location of the bar indicating the occurrence of that gene within the ranked gene list and the height of the
bars indicate the running GSEA enrichment score. (B) Genes being downregulated with treatment (List D) are signiﬁcantly enriched among genes
that are expressed at higher levels in an independent data set of airway epithelium from patients with chronic obstructive pulmonary disease (COPD)
relative to non-COPD controls (GSEA false discovery rate (FDR) <0.001).9 Similarly, genes upregulated after treatment with ﬂuticasone±salmeterol
(List U) are signiﬁcantly enriched among genes that are expressed at lower levels in patients with COPD in this independent data set (GSEA FDR
<0.001). The colour bar indicates the genes ranked according to their association with COPD (blue represents a decrease and red an increase in
gene expression in COPD). The vertical bars indicate the genes with a signiﬁcant increase or decrease in expression after 30-month treatment with
ﬂuticasone±salmeterol in Groningen and Leiden Universities study of Corticosteroids in Obstructive Lung Disease, with the location of the bar
indicating the occurrence of that gene within the ranked gene list and the height of the bar the running GSEA enrichment score.
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of activated B cells. In line with this, DUOX1 expression was
reported to be increased in airway epithelial cells from COPD
patients and rendered them more susceptible to rhinovirus infec-
tion.10 Thus, our observation that treatment with ﬂuticasone
±salmeterol reduces DUOXA1 expression may help to explain
why ICS are clinically effective in ﬂare-ups of the disease, as, for
example, reﬂected by the number of exacerbations in COPD.
Further, we observed a reduced expression of transmembrane
serine protease (TMPRSS)-4 and TMPRSS11 after treatment
with ﬂuticasone±salmeterol. Both TMPRSS4 and TMPRSS11
cleave haemagglutinin, which facilitates viral entry and spread in
human (bronchial) epithelial cells in vitro.11 In addition,
TMPRSS4 induces ‘epithelial to mesenchymal transition’ (EMT)
in epithelial cells.12 The latter may contribute to COPD patho-
genesis, since EMT may play a role in airway remodelling.13
Similar to TMPRSS4 and TMPRSS11, ABCA12 and GRHL3
exert their effects in epithelial cells, which are increasingly being
recognised to be of importance in COPD.14–18 The latter is in
line with our GSEA results showing that genes downregulated
after treatment are enriched for the KEGG pathway ‘epithelial
cell signalling’, whereas upregulated genes are enriched for the
KEGG pathway ‘focal adhesion’ and ‘gap junction’ and our self-
composed gene list related to epithelial barrier function. Finally,
both a reduced BNIPL and an increased PPM1K expression
reduce apoptosis.19 20
Taken together, our results indicate that treatment with ﬂuti-
casone±salmeterol decreases the expression of genes involved in
epithelial cell signalling, oxidative stress, remodelling and apop-
tosis, whereas it increases the expression of genes involved in
epithelial barrier function.
The strengths of our study include the long-term follow-up,
the repeated bronchial sampling and the randomised four-arm
design, allowing for an internal validation set.6 A total number of
50 out of 278 genes could be validated in the fourth treatment
arm. This should be considered a surprisingly high number, espe-
cially since these genes were actually validated two times: (1)
they changed in the same direction after 6-month ﬂuticasone
treatment and with 6-month and 30-month ﬂuticasone or ﬂutica-
sone/salmeterol treatment and (2) they reversed towards baseline
after ﬂuticasone withdrawal. There are also some limitations
inherent in our study. First, bronchial biopsies were investigated
containing a mix of both resident and inﬂammatory cell types.
We previously reported that 30-month treatment with ﬂuticasone
±salmeterol reduces the number of macrophages, mast cells,
CD4 and CD8 cells and increases the number of neutrophils and
the percentage intact epithelium relative to placebo.6 Because
these changes could potentially affect airway gene expression sig-
natures, we repeated our analyses with adjustment for changes in
inﬂammatory cell numbers and found that this had little effect on
the results. Second, although all bronchial biopsies were immedi-
ately snap-frozen and stored at −80°C, some degree of RNA deg-
radation had already occurred as reﬂected by relatively low RIN
scores, especially for the more remote samples collected in the
study; we therefore adjusted for RNA integrity in all analyses.
Nevertheless, we are conﬁdent that our data are reliable since
treatment-induced changes in gene expression were consistent
between the 6 and 30 months time points and were validated in
the fourth GLUCOLD study arm and additionally with PCR.
Finally, the effect of treatment with ICS on the annual rate of
decline in FEV1 was larger in the GLUCOLD study than in
earlier studies. A possible explanation for this may be that the
GLUCOLD study was carried out in steroid-naïve subjects.
Therefore, the problem of selective drop-out by subjects, who
thought that the placebo did not work as well as the treatment
they had before the study, was prevented. In addition, the major-
ity of patients in the GLUCOLD study demonstrated airway
hyperresponsiveness as well as a modest reversibility of FEV1.
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In conclusion, we performed longitudinal genome-wide gene
expression analysis on bronchial biopsies of well-characterised
COPD patients who participated in a randomised placebo-
controlled trial with a long follow-up of 30 months. Our ﬁnd-
ings support the paradigm of a molecular ‘ﬁeld of injury’ in the
airway of smokers with COPD and provide evidence, for the
ﬁrst time, that this ﬁeld of injury is dynamic with COPD treat-
ment and holds the potential to serve as an intermediate marker
of therapeutic efﬁcacy.22 23 It has also provided much needed
insight into the biological pathways that reﬂect and potentially
mediate treatment-induced clinical improvement in COPD.
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